(April 22, 2024, 2:11 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on April 22 denied a petition for a writ of certiorari by Vanda Pharmaceuticals Inc., which sought to undo findings that four patents relating to the use of tasimelteon to treat the sleep-wake disorder known as “non-24” would have been obvious to a person of skill in the art (POSITA)....